The behavior of PLGA microspheres containing rifampicin in alveolar macrophages

Colloids and Surfaces B: Biointerfaces

Volumn 76, Issue 1, 2010, Pages 151-157

  Onoshita, T ^a   Shimizu, Y ^a   Yamaya, N ^a   Miyazaki, M ^a   Yokoyama, M ^a   Fujiwara, N ^a   Nakajima, T ^a   Makino, K ^a   Terada, H ^a   Haga, M ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Alveolar macrophage; Microsphere; Phagosome lysosome fusion; PLGA; Rifampicin

Indexed keywords

ALVEOLAR MACROPHAGE; ALVEOLAR MACROPHAGES; AVERAGE DIAMETER; BIOCOMPATIBLE POLYMER; CYTOSOLS; DRUG DELIVERY TOOLS; ENERGY DEPENDENT; GLYCOLIC ACIDS; MICROSCOPIC STUDY; PLGA MICROSPHERES; PULMONARY DRUG DELIVERY;

CELL CULTURE; CONTROLLED DRUG DELIVERY; METABOLISM; MICROSPHERES; SULFUR COMPOUNDS;

MACROPHAGES;

MICROSPHERE; POLYGLACTIN; RIFAMPICIN;

ANIMAL CELL; ARTICLE; CELL TRANSPORT; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG UPTAKE; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELL LINE; HYDROGEN-ION CONCENTRATION; LACTIC ACID; MACROPHAGES, ALVEOLAR; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; POLYGLYCOLIC ACID; RATS; RIFAMPIN; TIME FACTORS;

PHAGO; RATTUS;

EID: 74149094512     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2009.10.036     Document Type: Article

References (44)

1. WHO REPORT 2009, Global Tuberculosis Control, 2007.
2. Swaminathan S N.G. HIV and tuberculosis in India. J. Biosci. 33 (2008) 527-537
3. Flannagan R.S., Cosio G., and Grinstein S. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat. Rev. Microbiol. 7 (2009) 355-366
4. Pethe K S.D., Alonso S., Anderson J., Wang C., and Russell D.G. Isolation of Mycobacterium tuberculosis mutants defective in the arrest of phagosome maturation. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 13642-13647
5. Sturgill-Koszycki S., Schlesinger P.H., Chakraborty P., Haddix P.L., Collins H.L., Fok A.K., Allen R.D., Gluck S.L., Heuser J., and Russell D.G. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263 (1994) 678-681
6. Pablos-MÈndez A K.C., Barr R.G., Lerner B.H., and Frieden T.R. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am. J. Med. 102 (1997) 164-170
7. W.H.O., Adherence to Long-Term Therapies-Evidence for Action, 2003.
8. Davidson P.T., and Le H.Q. Drug treatment of tuberculosis-1992. Drugs 43 (1992) 651-673
9. RJ O.B. Drug-resistant tuberculosis: etiology, management and prevention. Semin. Respir. Infect. 9 (1994) 104-112
10. C.f.D.C.(CDC) a.P. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55 (2006) 301-305
11. Kameda K., Kawabata S., and Shirai S. A case of acute hepatitis occurred during treatment with isoniazid and rifampicin (author's transl). Kekkaku 55 (1980) 247-251
12. Schaberg T. The dark side of antituberculosis therapy: adverse events involving liver function. Eur. Respir. J. 8 (1995) 1247-1249
13. Bouke D.M.I., de Jong C., Corbett E.L., and Small P.M. Clinical management of tuberculosis in the context of HIV infection. Annu. Rev. Med. 55 (2004) 283-301
14. Furesz S., Scotti R., Pallanza R., and Mapelli E. Rifampicin: a new rifamycin. 3. Absorption, distribution, and elimination in man. Arzneimittelforschung 17 (1967) 534-537
15. Sano M., and Hakusui H. Urinary metabolites of rifampicin. Jpn. J. Antibiot. 23 (1970) 416-420
16. Maggi A.V., Sensi N., and Rifamycins P. X.L.I. A new class of active semisynthetic rifamycins. N-substituted aminomethyl derivatives of rifamycin SV 2. J. Med. Chem. 8 (1965) 790-793
17. A.G. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3 (1978) 108-127
18. Fu J., Fiegel J., Krauland E., and Hanes J. New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials 23 (2002) 4425-4433
19. Pandey R., and Khuller G.K. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. 55 (2005) 430-435
20. O'Hara P., and Hickey A.J. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm. Res. 17 (2000) 955-961
21. Makino K., Nakajima T., Shikamura M., Ito F., Ando S., Kochi C., Inagawa H., Soma G., and Terada H. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf. B: Biointerfaces 36 (2004) 35-42
22. Barrow E.L., Winchester G.A., Staas J.K., Quenelle D.C., and Barrow W.W. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob. Agents Chemother. 42 (1998) 2682-2689
23. Anisimova S.I.G.Y.V., Peloquin C.A., and Heifets L.B. Nanoparticles as antituberculosis drugs carriers: effect on activity against mycobacterium tuberculosis in human moncyte-derived macrophages. J. Nanopart. Res. 2 (2000) 165-171
24. Dutt M., and Khuller G.K. Therapeutic efficacy of Poly(dl-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother. 45 (2001) 363-366
25. Sharma R., Saxena D., Dwivedi A.K., and Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 18 (2001) 1405-1410
26. Ahsan F., Rivas I.P., Khan M.A., and Torres Suarez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control. Rel. 79 (2002) 29-40
27. Suarez S., O'Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., and Hickey A.J. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrob. Chemother. 48 (2001) 431-434
28. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller G.K., and Prasad B. Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52 (2003) 981-986
29. Dutt M., and Khuller G.K. Liposomes and PLG microparticles as sustained release antitubercular drug carriers-an in vitro-in vivo study. Int. J. Antimicrob. Agents 18 (2001) 245-252
30. Dutt M., and Khuller G.K. Sustained release of isoniazid from a single injectable dose of poly (dl-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int. J. Antimicrob. Agents 17 (2001) 115-122
31. Ito F., and Makino K. Preparation and properties of monodispersed rifampicin-loaded poly(lactide-co-glycolide) microspheres. Colloids Surf. B: Biointerfaces 39 (2004) 17-21
32. Hirota K., Hasegawa T., Hinata H., Ito F., Inagawa H., Kochi C., Soma G., Makino K., and Terada H. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J. Control. Rel. 119 (2007) 69-76
33. Gallo G.G., and Radaelli P. Rifampicin. In: Florey K. (Ed). Analytical Profiles of Drug Substances 5 (1976), Academic Press, New York, NY pp. 467-575
34. Tewes F., Brillault J., Couet W., and Olivier J.C. Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J. Control. Rel. 129 (2008) 93-99
35. Hasegawa T., Iijima K., Hirota K., Nakajima T., Makino K., and Terada H. Exact determination of phagocytic activity of alveolar macrophages toward polymer microspheres by elimination of those attached to the macrophage membrane. Colloids Surf. B: Biointerfaces 63 (2008) 209-216
36. Foster K.A., Yazdanian M., and Audus K.L. Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium. J. Pharm. Pharmacol. 53 (2001) 57-66
37. Ueda M.J., Ito T., Ohnishi S., and Okada T.S. Phagocytosis by macrophages. I. Kinetics of adhesion between particles and phagocytes. J. Cell. Sci. 51 (1981) 173-188
38. Akhtar K.J.L.S. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres. Int. J. Pharm. 151 (1997) 57-67
39. Ito T., Ueda M.J., Okada T.S., and Ohnishi S. Phagocytosis by macrophages. II. The dissociation of the attachment and ingestion steps. J. Cell. Sci. 51 (1981) 189-201
40. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., and Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16 (2002) 1217-1226
41. Qaddoumi M.G., Ueda H., Yang J., Davda J., Labhasetwar V., and Lee V.H. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm. Res. 21 (2004) 641-648
42. Indik Z.K., Park J.G., Hunter S., Mantaring M., and Schreiber A.D. Molecular dissection of Fc gamma receptor-mediated phagocytosis. Immunol. Lett. 44 (1995) 133-138
43. Froystad M.K., Rode M., Berg T., and Gjoen T. A role for scavenger receptors in phagocytosis of protein-coated particles in rainbow trout head kidney macrophages. Dev. Comp. Immunol. 22 (1998) 533-549
44. Li L., and Schwendeman S.P. Mapping neutral microclimate pH in PLGA microspheres. J. Control. Rel. 101 (2005) 163-173